May 24, 2021
June 5, 2021 marks the 40th anniversary of the first description of Pneumocystis pneumonia in the setting of what we know as AIDS in 5 patients in Los Angeles – in the Centers for Disease Control’s Morbidity and Mortality Weekly Report (MMWR).These observations, by Dr. Michael Gottlieb, from UCLA, and Dr. Joel Weisman began to define the challenges that would shape the research and treatment age
March 23, 2021
Dr. Raphael Landovitz presented findings on injectable PrEP to CROI 2021. The conference highlighted that programmes to deliver injectable HIV medications must be practical and affordable. There is great enthusiasm from patients for long-acting agents, while some healthcare providers have concerns about operational challenges. Several details about how injectable cabotegravir and rilpivirine shoul
February 12, 2021
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part
The main purpose of the study is to evaluate the efficacy and safety of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization. The primary hypothesis of the study is that the administration of ISL QM as PreP reduces the incidence rate per year of the confirmed HIV-1 infections compared to the background incidence rates. You may qualify for this study if you are between 18-29 years old and: Are a cisgender male (male at birth) or a transgender female Are sexually active with cisgender male or transgender female partners Are considered at high risk for acquiring HIV-1 infection Principal Investigator: Raphael Landovitz, MD, MSc For more information, including possible risks and benefits of being in this study, please contact the UCLA study team at: [email protected] 310-843-2015 *There are limits to the confidentiality of email communications. Do not include any sensitive health information if you choose to contact the study team via email.
A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1 Scientists want to know if a combination of an investigational long-acting HIV drug and a monoclonal antibody given together are safe and effective at maintaining undetectable viral load in people living with HIV. You may qualify if you: are HIV+ are at least 18 years old are on a stable HIV regimen with an undetectable viral load for at least 2 years have a CD4 count above 350 have no active hepatitis B or C PARTICIPANTS WILL BE COMPENSATED Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the study team at: [email protected] 310-557-9062
Vaccination for Hepatitis B in people with HIV does not always work. A new vaccine has been approved that may provide a better response. The UCLA CARE Center is doing a study to look at whether this new vaccine will be more effective than the current standard Hepatitis B vaccine. Basic eligibility criteria: Living with HIV and on HIV treatment for at least 8 weeks Previously received vaccines for hep B but they didn't work OR have never received hep B vaccine No history of hep B infection T-cell count > 100 Viral load < 1,000 Principal Investigator: Kara Chew, MD, MSc For more information contact our outreach team at: [email protected] 310-557-9062 *There are limitations to the confidentiality of email communications. Do not include any sensitive health information if you choose to contact the study team via email.